Alloplex’s founder and CEO, Dr. Frank Borriello, will be attending the upcoming LSX Leaders Congress in Boston on September 13 and 14 at the Hynes Convention Centre. Alloplex is seeking strategic partners and investors to support a de-risked Phase 2 ready clinical stage cellular therapy opportunity with highly di...
Topic: Backgrounder
-
August 22, 2023
Alloplex seeks strategic partners and investor meetings at LSX Leaders Congress (Boston, September 2023)
SUPLEXA cellular therapy, a highly differentiated therapy with exceptionally broad promise, has demonstrated single-agent activity in end-stage solid cancer patients
Read More -
November 15, 2021
Alloplex presents poster describing novel tumor-killing cells at SITC 2021 Conference
Non-engineered SUPLEXA cells demonstrate potent activity against patient-derived cancer organoids in vitro.
Today Alloplex Biotherapeutics released details of its abstract entitled Potent Tumor Organoid Infiltration and Killing by PBMC-Derived Effector Cells presented at SITC 2021. Alloplex’s abstract shows that the organization can generate tumor-killing cells from PBMCs using a clinical grade manufacturing process for SU...
Read More